Skip to main content

Table 3 Frequencies of CYP2D6 and CYP3A gene variants in the investigated TAM-treated breast cancer patients (n = 40)

From: Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients

Gene   Premenopausal (n = 20) Postmenopausal (n = 20)
CYP2D6
 Activity score Function Frequencies of gene variants
  0 PM 0 0
  0.5 IM 0.15 0
  1 Slow NM 0.30 0.2
  1.5 NM 0.25 0.35
  2 NM 0.25 0.35
   > 2 UM 0 0
  others 0.05 0.10
CYP3A5
 *3 Variant   
  AA (*3/*3) 0.65 0.7
  AG (*3/*1) 0.35 0.2
  GG (*1/*1) 0 0.1
CYP3A4
 *1b Variant   
  AA (*1/*1) 0.8 0.7
  AG (*1/*1b) 0.2 0.3
  GG (*1b/*1b) 0 0
 *22 Variant   
  CC (*1/*1) 0.9 0.95
  CT (*1/*22) 0.1 0.05
  TT (*22/*22) 0 0